UV0155041 is a potent, positive allosteric modulator/allosteric agonist at mGlu4 receptors (EC50 = 798 and 693 nM at human and rat mGlu4 receptors respectively).
Physicochemical Properties
| Molecular Formula | C14H15CL2NO3 |
| Molecular Weight | 316.178 |
| Exact Mass | 315.043 |
| Elemental Analysis | C, 53.18; H, 4.78; Cl, 22.42; N, 4.43; O, 15.18 |
| CAS # | 1093757-42-6 |
| Related CAS # | (1R,2S)-VU0155041; 1263273-14-8; VU0155041 sodium; 1259372-69-4 |
| PubChem CID | 888023 |
| Appearance | Pale purple to purple solid powder |
| LogP | 4.472 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 3 |
| Heavy Atom Count | 20 |
| Complexity | 367 |
| Defined Atom Stereocenter Count | 2 |
| SMILES | ClC1=CC(NC([C@H]2[C@@H](C(O)=O)CCCC2)=O)=CC(Cl)=C1 |
| InChi Key | VSMUYYFJVFSVCA-NWDGAFQWSA-N |
| InChi Code | InChI=1S/C14H15Cl2NO3/c15-8-5-9(16)7-10(6-8)17-13(18)11-3-1-2-4-12(11)14(19)20/h5-7,11-12H,1-4H2,(H,17,18)(H,19,20)/t11-,12+/m0/s1 |
| Chemical Name | (1R,2S)-2-[(3,5-dichlorophenyl)carbamoyl]cyclohexane-1-carboxylic acid |
| Synonyms | UV0155041; UV-0155041; UV 0155041 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | Human mGlu4 ( EC50 = 798 nM ); Rat mGlu4 ( EC50 = 693 nM ) |
| ln Vitro | VU0155041 (10 μM) has no effect on NMDA receptor currents in striatal medium spiny neurons[1]. |
| ln Vivo | VU0155041 (31 nmol, 93 nmol; i.c.v.) reverses catalepsy brought on by the dopamine D2 receptor antagonist haloperidol (1.5 mg/kg, i.p.) in rats[1]. VU0155041 (93 nnmol, 316 nmol; i.c.v.) reversibly akinesia in rats induced by serpine (HY-N0480)[1]. |
| Animal Protocol |
Third ventricle cannulated (TVC) Male Sprague-Dawley rats (225-255 g) 31 nmol, 93 nmol (10 μL) Intracerebroventrical injection, after the Haloperidol (1.5 mg/kg) treatment 2 hours |
| References |
[1]. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol Pharmacol. 2008 Nov; 74(5): 1345-58. |
Solubility Data
| Solubility (In Vitro) | DMSO: ~100 mg/mL (~316.3 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.91 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (7.91 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1628 mL | 15.8138 mL | 31.6276 mL | |
| 5 mM | 0.6326 mL | 3.1628 mL | 6.3255 mL | |
| 10 mM | 0.3163 mL | 1.5814 mL | 3.1628 mL |